CN103969445B - The preparation of heme-manganese dioxide composites and the method for detecting human IgG thereof - Google Patents
The preparation of heme-manganese dioxide composites and the method for detecting human IgG thereof Download PDFInfo
- Publication number
- CN103969445B CN103969445B CN201410192532.XA CN201410192532A CN103969445B CN 103969445 B CN103969445 B CN 103969445B CN 201410192532 A CN201410192532 A CN 201410192532A CN 103969445 B CN103969445 B CN 103969445B
- Authority
- CN
- China
- Prior art keywords
- human igg
- heme
- solution
- manganese dioxide
- hole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000000243 solution Substances 0.000 claims abstract description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 18
- 150000003278 haem Chemical class 0.000 claims abstract description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 claims abstract description 4
- 230000003647 oxidation Effects 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 241000283707 Capra Species 0.000 claims description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 8
- 229940098773 bovine serum albumin Drugs 0.000 claims description 8
- 238000002835 absorbance Methods 0.000 claims description 7
- 239000004793 Polystyrene Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 229920002223 polystyrene Polymers 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000007979 citrate buffer Substances 0.000 claims description 5
- 238000004737 colorimetric analysis Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- 239000008366 buffered solution Substances 0.000 claims 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- 239000012467 final product Substances 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Inorganic materials O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 abstract description 27
- 238000001514 detection method Methods 0.000 abstract description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 abstract description 6
- 239000008055 phosphate buffer solution Substances 0.000 abstract description 5
- 239000000427 antigen Substances 0.000 abstract description 4
- 102000036639 antigens Human genes 0.000 abstract description 4
- 108091007433 antigens Proteins 0.000 abstract description 4
- 238000003018 immunoassay Methods 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 239000003550 marker Substances 0.000 abstract description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 abstract description 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 2
- 238000004458 analytical method Methods 0.000 abstract description 2
- 102000018358 immunoglobulin Human genes 0.000 abstract description 2
- 102000003992 Peroxidases Human genes 0.000 abstract 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 3
- 229940025294 hemin Drugs 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开了亚铁血红素—二氧化锰复合物的制备及其用于检测人IgG的方法。本发明将亚铁血红素在氨水作用下溶于磷酸盐缓冲溶液,再依次加入MnAc2溶液和NaOH溶液反应,制得亚铁血红素—二氧化锰复合物(Hemin-MnO2);Hemin-MnO2具有过氧化物酶活性,能催化双氧水氧化TMB使其由无色变为蓝色,通过传统的“三明治”夹心结构法,以Hemin-MnO2作为兔抗人IgG标记物,来进行人体免疫球蛋白IgG抗原的检测,使用Hemin-MnO2的比色免疫法检测具有稳定性好、灵敏度高、选择性好、重现性优、分析速度快等优点;该免疫传感方法简单,价格低廉,肉眼即可观察其颜色变化,具有广泛的应用前景。The invention discloses the preparation of heme-manganese dioxide complex and its method for detecting human IgG. In the present invention, the heme is dissolved in the phosphate buffer solution under the action of ammonia water, and the MnAc 2 solution and the NaOH solution are added in turn to react to obtain the heme-manganese dioxide complex (Hemin-MnO 2 ); Hemin- MnO 2 has peroxidase activity, which can catalyze hydrogen peroxide to oxidize TMB to turn it from colorless to blue. Through the traditional "sandwich" sandwich structure method, Hemin-MnO 2 is used as a rabbit anti-human IgG marker to conduct human For the detection of immunoglobulin IgG antigen, the colorimetric immunoassay using Hemin- MnO2 has the advantages of good stability, high sensitivity, good selectivity, excellent reproducibility, and fast analysis speed; the immunosensing method is simple and inexpensive It is cheap, its color change can be observed with naked eyes, and has wide application prospects.
Description
技术领域 technical field
本发明涉及亚铁血红素—二氧化锰复合物的制备及其用于检测人IgG的方法,属于生物传感领域。 The invention relates to the preparation of a heme-manganese dioxide complex and a method for detecting human IgG, belonging to the field of biosensing.
背景技术 Background technique
近年来,新型生物传感技术的构建及应用发展迅速,在临床早期诊断、环境监测、食品检测等领域得到了广泛应用。而很多传感方法及其应用受仪器及相关技术专业人员的限制而无法在许多发展中国家普及,所以构建一种简单、经济且无需借助精密仪器设备的传感方法成为科研热门研究领域。基于颜色变化来实现检测的生物免疫传感方法,因其反应迅速、方便经济、操作简单等特点而受到众多科研工作者亲睐。 In recent years, the construction and application of new biosensing technologies have developed rapidly, and have been widely used in early clinical diagnosis, environmental monitoring, food testing and other fields. However, many sensing methods and their applications cannot be popularized in many developing countries due to the limitations of instruments and related technical professionals. Therefore, building a simple, economical sensing method that does not require the use of sophisticated instruments and equipment has become a hot research field. The biological immunosensing method based on color change is favored by many scientific researchers because of its rapid response, convenience, economy, and simple operation.
现有的定量检测人IgG的方法包括电化学检测法,荧光检测法、化学发光法等。但这些方法依赖于一定的仪器设备,而且不能同一时间检测多种样品,所耗时间较长。 Existing methods for quantitative detection of human IgG include electrochemical detection, fluorescence detection, chemiluminescence and the like. However, these methods rely on certain instruments and equipment, and cannot detect multiple samples at the same time, which takes a long time.
发明内容 Contents of the invention
本发明的目的是在于提供一种结构稳定、具有过氧化物酶活性的亚铁血红素—二氧化锰复合物的制备方法,该制备方法简单、成本低。 The object of the present invention is to provide a method for preparing a heme-manganese dioxide complex with stable structure and peroxidase activity, which is simple and low in cost.
本发明的另一个目的是在于提供了一种基于亚铁血红素—二氧化锰复合物的检测人IgG的方法,该方法利用亚铁血红素—二氧化锰复合物催化双氧水氧化3,3’,5,5’-四甲基联苯胺(TMB)产生颜色变化,实现了人IgG检测,该方法相对传统的酶联免疫法相比,不需要使用酶作为抗体标记物,具有稳定性好、简单、灵敏度高、选择性好、价格低廉等优点,实现了人体内免疫球蛋白IgG的高通量检测。 Another object of the present invention is to provide a method for detecting human IgG based on the heme-manganese dioxide complex, which utilizes the heme-manganese dioxide complex to catalyze the oxidation of 3,3' ,5,5'-Tetramethylbenzidine (TMB) produces a color change and realizes the detection of human IgG. Compared with the traditional enzyme-linked immunosorbent method, this method does not need to use enzymes as antibody markers, and has good stability and simplicity. , high sensitivity, good selectivity, low price and other advantages, realize the high-throughput detection of IgG in human body.
本发明提供了一种亚铁血红素—二氧化锰复合物的制备方法,该制备方法是将亚铁血红素与磷酸盐缓冲溶液混合后,加入氨水促使亚铁血红素溶解,再在混合溶液中依次加入过量的MnAc2溶液和过量的NaOH溶液,搅拌均匀,再离心处理后,除去未反应完的MnAc2和NaOH,即得。 The invention provides a preparation method of a heme-manganese dioxide complex. The preparation method is to mix the heme with a phosphate buffer solution, add ammonia water to promote the dissolution of the heme, and then mix the heme in the mixed solution. Add excess MnAc 2 solution and excess NaOH solution in turn, stir evenly, and after centrifugation, remove unreacted MnAc 2 and NaOH, that is.
本发明的亚铁血红素—二氧化锰复合物的制备方法包括以下优选方案: The preparation method of the heme-manganese dioxide complex of the present invention includes the following preferred schemes:
所述的离心处理是在8000~10000rpm的速率下离心15~25min。 The centrifugation treatment is centrifugation at a speed of 8000-10000 rpm for 15-25 minutes.
所述的磷酸盐缓冲溶液pH为7.4。 The pH of the phosphate buffer solution is 7.4.
所制得的亚铁血红素—二氧化锰复合物PBS缓冲溶液清洗2~3遍,于不大于4℃的环境下储存备用。 The prepared heme-manganese dioxide complex PBS buffer solution is washed 2 to 3 times, and stored in an environment not higher than 4°C for future use.
本发明还提供了一种基于亚铁血红素—二氧化锰复合物的检测人IgG的方法,该方法是在聚苯乙烯96孔板的各个孔的底表面先固定羊抗人IgG,并用牛血清白蛋白将所述各个孔的底表面封闭;再在所述牛血清白蛋白封闭过的各个孔的底表面分别组装不同摩尔量的人IgG后,进一步组装亚铁血红素—二氧化锰复合物修饰兔抗人IgG;组装完成后,在各个孔中加入等量的含H2O2和3,3’,5,5’-四甲基联苯胺的柠檬酸缓冲液进行反应,反应完成后,用酶标仪测定各个孔中3,3’,5,5’-四甲基联苯胺的氧化产物在652nm的吸光度值,进行比色分析。 The present invention also provides a method for detecting human IgG based on the heme-manganese dioxide complex. The method is to first fix goat anti-human IgG on the bottom surface of each well of a polystyrene 96-well plate, and use bovine Serum albumin seals the bottom surface of each well; and then assembles different molar amounts of human IgG on the bottom surface of each well sealed by bovine serum albumin, and then further assembles the heme-manganese dioxide composite After the assembly is completed, add an equal amount of citrate buffer containing H 2 O 2 and 3,3',5,5'-tetramethylbenzidine to each well for reaction, and the reaction is complete Afterwards, the absorbance value at 652 nm of the oxidation product of 3,3',5,5'-tetramethylbenzidine in each well was measured with a microplate reader for colorimetric analysis.
本发明的基于亚铁血红素—二氧化锰复合物的检测人IgG的方法还包括以下优选方案: The method for detecting human IgG based on the heme-manganese dioxide complex of the present invention also includes the following preferred schemes:
优选的方法是先在聚苯乙烯96孔板的各个孔中加入羊抗人IgG静置8~12h,除去多余的羊抗人IgG,再在所述的各个孔中加入牛血清白蛋白静置2~3h,除去多余的牛血清白蛋白;再在各个孔中分别加入等体积不同浓度的人IgG溶液,在37℃下温育0.8~1.2h,除去各孔中的剩余人IgG溶液,再在各个孔中加入亚铁血红素—二氧化锰复合物修饰兔抗人IgG,在37℃下温育1.2~1.7h,除去各孔中的剩余亚铁血红素—二氧化锰复合物修饰兔抗人IgG;最后在各个孔中加入等量的含H2O2和3,3’,5,5’-四甲基联苯胺的柠檬酸缓冲液进行反应10~20min后,用酶标仪测定各个孔中3,3’,5,5’-四甲基联苯胺的氧化产物在652nm的吸光度值,进行比色分析。 The preferred method is to add goat anti-human IgG to each well of a polystyrene 96-well plate and let it stand for 8 to 12 hours to remove excess goat anti-human IgG, then add bovine serum albumin to each well and let stand 2~3h, remove excess bovine serum albumin; then add equal volumes of human IgG solutions of different concentrations to each well, incubate at 37°C for 0.8~1.2h, remove the remaining human IgG solution in each well, and then Add heme-manganese dioxide complex-modified rabbit anti-human IgG to each well, incubate at 37°C for 1.2-1.7h, and remove the remaining heme-manganese dioxide complex-modified rabbit in each well. Anti-human IgG; finally, add an equal amount of citrate buffer containing H 2 O 2 and 3,3',5,5'-tetramethylbenzidine to each well for 10-20 minutes of reaction, and use a microplate reader to The absorbance value at 652 nm of the oxidation product of 3,3',5,5'-tetramethylbenzidine in each well was measured for colorimetric analysis.
所述的亚铁血红素—二氧化锰复合物修饰兔抗人IgG通过以下方法制备得到,将所述的亚铁血红素—二氧化锰复合物依次置于壳聚糖溶液、戊二醛溶液和 兔抗人IgG中反应、离心处理,即得。 The rabbit anti-human IgG modified by the heme-manganese dioxide complex is prepared by the following method, placing the heme-manganese dioxide complex in chitosan solution and glutaraldehyde solution in sequence React with rabbit anti-human IgG and centrifuge to obtain it.
所述的亚铁血红素—二氧化锰复合物依次置于0.3~0.8wt%的壳聚糖溶液中反应1.8~2.2h,离心3~7min,于0.2~0.3wt%的戊二醛溶液中反应0.4~0.6h,离心3~7min,于40~60μg mL-1的兔抗人IgG中0.8~1.2h,离心处理后,将离心物分散到磷酸盐缓冲溶液中,得到亚铁血红素—二氧化锰复合物修饰兔抗人IgG溶液。所述的磷酸盐缓冲溶液pH值优选为pH=7.4。所述的亚铁血红素—二氧化锰复合物修饰兔抗人IgG溶液浓度为1mg mL-1。 The heme-manganese dioxide complex is sequentially placed in 0.3-0.8wt% chitosan solution to react for 1.8-2.2h, centrifuged for 3-7min, and placed in 0.2-0.3wt% glutaraldehyde solution React for 0.4~0.6h, centrifuge for 3~7min, put in 40~60μg mL -1 rabbit anti-human IgG for 0.8~1.2h, after centrifugation, disperse the centrifuge in phosphate buffer solution to obtain heme— Manganese dioxide complex modified rabbit anti-human IgG solution. The pH value of the phosphate buffer solution is preferably pH=7.4. The concentration of the rabbit anti-human IgG solution modified by the heme-manganese dioxide complex is 1 mg mL -1 .
本发明的有益效果:本发明首次通过简单的方法合成了亚铁血红素—二氧化锰复合物(Hemin-MnO2),发现其具有过氧化物酶活性,能催化双氧水氧化3,3’,5,5’-四甲基联苯胺(TMB)使其由无色变为蓝色;本发明申请进一步将亚铁血红素—二氧化锰复合物作为抗体标记物应用于人IgG的检测,具有较高灵敏度,用肉眼即可辨别其颜色变化。本发明采用传统的“三明治”夹心结构法,在聚苯乙烯96孔微量滴定板上固定羊抗人IgG,用所合成的Hemin-MnO2复合物作为兔抗人IgG标记物,来进行人体免疫球蛋白IgG抗原的检测,发现随着抗原浓度增大,最终氧化的产物颜色也出现有规律的变化(无色—浅蓝—深蓝),可以借助酶标仪测定的吸光度值实现人IgG的定量分析。使用Hemin-MnO2复合物的比色免疫法检测相对现有技术中传统的酶联免疫法,不需要使用酶作为抗体标记物,具有稳定性好、灵敏度高、选择性好、重现性优、分析速度快等优点。该免疫传感方法简单,价格低廉,肉眼即可观察其颜色变化,在生物技术、生物测定和生物医学方面具有潜在的应用前景。 Beneficial effects of the present invention: the present invention synthesized the heme-manganese dioxide complex (Hemin-MnO 2 ) through a simple method for the first time, and found that it has peroxidase activity and can catalyze the oxidation of 3,3', 5,5'-tetramethylbenzidine (TMB) makes it change from colorless to blue; the application of the present invention further applies the heme-manganese dioxide complex to the detection of human IgG as an antibody marker, which has With high sensitivity, the color change can be discerned with the naked eye. The present invention adopts the traditional "sandwich" sandwich structure method, immobilizes goat anti-human IgG on a polystyrene 96-well microtiter plate, and uses the synthesized Hemin- MnO2 complex as a rabbit anti-human IgG marker to carry out human immunization In the detection of globulin IgG antigen, it was found that as the concentration of the antigen increased, the color of the final oxidized product also changed regularly (colorless-light blue-dark blue), and the quantification of human IgG can be realized by means of the absorbance value measured by a microplate reader analyze. Compared with the traditional enzyme-linked immunoassay in the prior art, the colorimetric immunoassay using the Hemin-MnO 2 complex does not need to use enzymes as antibody markers, and has good stability, high sensitivity, good selectivity, and excellent reproducibility , analysis speed and so on. The immunosensing method is simple, inexpensive, and its color change can be observed with naked eyes, and has potential application prospects in biotechnology, bioassay and biomedicine.
附图说明 Description of drawings
【图1】为本发明实施例1制备的Hemin-MnO2复合物的透射电子显微镜图像。 [Fig. 1] is a transmission electron microscope image of the Hemin-MnO 2 composite prepared in Example 1 of the present invention.
【图2】为本发明实施例1制备的Hemin-MnO2复合物的能量色散X射线光谱图。 [Fig. 2] is the energy dispersive X-ray spectrogram of the Hemin-MnO 2 composite prepared in Example 1 of the present invention.
【图3】为本发明实施例1制备的Hemin-MnO2复合物以及Hemin、MnO2和TMB催化双氧水氧化TMB的显色变化图以及相应的吸光度—波长曲线图;1为TMB;2为MnO2,3为Hemin,4为Hemin-MnO2复合物;显色变化图从上到下依次对应曲线4、3、2和1。 [Fig. 3] is the Hemin-MnO 2 composite prepared in Example 1 of the present invention and Hemin, MnO 2 and TMB catalyzed hydrogen peroxide oxidation TMB color change chart and the corresponding absorbance-wavelength curve; 1 is TMB; 2 is MnO 2 , 3 is Hemin, and 4 is Hemin-MnO 2 complex; the color change chart corresponds to curves 4, 3, 2 and 1 from top to bottom.
【图4】为不同浓度的本发明实施例1制备的Hemin-MnO2复合物催化氧化等量TMB的显色变化图以及相应的吸光度—波长曲线图;曲线9、8、7、6和5依次对应Hemin-MnO2复合物浓度到由高到低,显色变化图从上到下依次对应9、8、7、6和5。 [Fig. 4] Hemin- MnO complex catalyzed oxidation equivalent TMB color change diagram and corresponding absorbance-wavelength curve diagram for different concentrations prepared in Example 1 of the present invention; Curves 9, 8, 7, 6 and 5 Corresponding to the Hemin-MnO 2 complex concentration from high to low, the color change diagram corresponds to 9, 8, 7, 6 and 5 from top to bottom.
【图5】为是本发明实施例1制备的Hemin-MnO2复合物采用双抗夹心法修饰后的免疫传感器测定不同浓度人IgG抗原所得的标准曲线图。 [ FIG. 5 ] is a standard curve diagram of the Hemin-MnO 2 complex prepared in Example 1 of the present invention using the immunosensor modified by the double-antibody sandwich method to measure different concentrations of human IgG antigen.
具体实施方式 Detailed ways
以下实施例旨在进一步说明本发明内容,而不是限制本发明的保护范围。 The following examples are intended to further illustrate the content of the present invention, but not to limit the protection scope of the present invention.
实施例1 Example 1
新型亚铁血红素—二氧化锰复合物(Hemin-MnO2)的合成:将15mg的Hemin与10mL pH=7.4的PBS缓冲溶液混合后,加入50μL的氨水,搅拌溶解,然后边搅拌边加入1.6mL100mM的MnAc2溶液,室温下搅拌5min,然后加入100μL1M的NaOH溶液,继续搅拌6~8h,最终得到Hemin-MnO2复合物,然后在9000rpm下离心20min,除去多于的MnAc2和NaOH,再用PBS缓冲溶液清洗2~3遍,最后将离心得到的产物储存在4℃的冰箱中备用。 Synthesis of a novel heme-manganese dioxide complex (Hemin-MnO 2 ): mix 15 mg of Hemin with 10 mL of PBS buffer solution with pH=7.4, add 50 μL of ammonia water, stir to dissolve, and then add 1.6 mL of 100mM MnAc 2 solution, stirred at room temperature for 5min, then added 100μL of 1M NaOH solution, continued to stir for 6-8h, and finally obtained the Hemin-MnO 2 complex, and then centrifuged at 9000rpm for 20min to remove excess MnAc 2 and NaOH, and then Wash with PBS buffer solution for 2-3 times, and finally store the product obtained by centrifugation in a refrigerator at 4°C for future use.
本发明的亚铁血红素—二氧化锰复合物修饰兔抗人IgG合成方法:将合成的Hemin-MnO2复合物分散到0.5wt%的壳聚糖溶液中,反应2h,离心5min;再用0.25wt%的戊二醛分散0.5h,离心5min;然后用50μg mL-1的兔抗人IgG与之反应1h,离心;最后将其分散到pH=7.4的PBS中,制得1mg mL-1的溶液,储存在4℃的冰箱中备用。 Hemin-manganese dioxide complex modified rabbit anti-human IgG synthesis method of the present invention: the synthesized Hemin- MnO complex is dispersed in 0.5wt% chitosan solution, reacted for 2h, and centrifuged for 5min; 0.25wt% glutaraldehyde was dispersed for 0.5h, centrifuged for 5min; then reacted with 50μg mL -1 rabbit anti-human IgG for 1h, centrifuged; finally dispersed in PBS with pH=7.4 to prepare 1mg mL -1 The solution was stored in a refrigerator at 4 °C for later use.
本发明的亚铁血红素—二氧化锰复合物用于免疫分析检测对免疫球蛋白IgG的检测方法:将150μL羊抗人IgG(用缓冲液稀释至10μg mL-1)加入聚苯乙烯96孔微量滴定板中,在4℃下孵育一整夜,将抗体固定到孔中。未固定的羊抗人IgG溶液用300μL洗涤缓冲液冲洗三次洗去。接着在37℃下,加入250μL封闭缓冲液,温育2.5h,减少人IgG的非特异吸附,过量的BSA则用300μL的洗涤缓冲液冲洗三次。以pH=7.4的PBS溶液分别配制不同浓度的IgG溶液(0,1,2,5,10,50,100,500,1000pg mL-1),然后分别将150μL所配不同浓度的人IgG溶液加入孔中,孵育1h,再冲洗三次。随后加入150μLHemin-MnO2修饰兔抗人 IgG,孵育1.5h。在用300μL的洗涤缓冲液冲洗四次。最后,在每个孔中加入150μL含4.3mM双氧水的柠檬酸缓冲液配制的2.5mM TMB,反应15min,继而用酶标仪测定TMB氧化产物的吸光度值,制得的标准曲线如图5所示。 The heme-manganese dioxide complex of the present invention is used in the immunoassay to detect immunoglobulin IgG. The detection method: add 150 μL goat anti-human IgG (diluted to 10 μg mL -1 with buffer) into polystyrene 96 wells Incubate overnight at 4°C in a microtiter plate to immobilize the antibody into the wells. The unfixed goat anti-human IgG solution was washed three times with 300 μL washing buffer to wash away. Then at 37°C, 250 μL of blocking buffer was added and incubated for 2.5 hours to reduce the non-specific adsorption of human IgG, and excess BSA was washed three times with 300 μL of washing buffer. Prepare different concentrations of IgG solutions (0, 1, 2, 5, 10, 50, 100, 500, 1000 pg mL -1 ) with PBS solution at pH = 7.4, and then add 150 μL of human IgG solutions with different concentrations to wells, incubated for 1 h, and washed three times. Then 150 μL of Hemin-MnO 2 modified rabbit anti-human IgG was added and incubated for 1.5 h. Wash four times with 300 μL of wash buffer. Finally, add 150 μL of 2.5 mM TMB prepared in citrate buffer containing 4.3 mM hydrogen peroxide to each well, react for 15 min, and then use a microplate reader to measure the absorbance of TMB oxidation products. The prepared standard curve is shown in Figure 5 .
实施例2 Example 2
利用亚铁血红素—二氧化锰复合物用于临床免疫分析检测对人血清中人IgG回收率的测定:将人血清样品用pH=7.4的PBS缓冲液逐级稀释到10-10倍,然后加入不同浓度的0pg mL-1、10pg mL-1、50pg mL-1、100pg mL-1和500pgmL-1的人IgG溶液。以加入0pg mL-1人IgG的纯血清溶液为空白参比溶液,按照实施例1的具体操作测定TMB氧化产物的吸光度值,制得回收率如表1,从表1数据可以看出人IgG回收率高,可以证明实施例1的检测方法的可行性和准确性。 Using the heme-manganese dioxide complex for clinical immunoassay detection to measure the recovery rate of human IgG in human serum: the human serum sample is diluted to 10-10 times with PBS buffer solution of pH=7.4, and then Human IgG solutions at different concentrations of 0pg mL -1 , 10pg mL -1 , 50pg mL -1 , 100pg mL -1 and 500pg mL -1 were added. Taking the pure serum solution added with 0 pg mL -1 human IgG as blank reference solution, the absorbance value of the TMB oxidation product was measured according to the specific operation of Example 1, and the recovery rate obtained is shown in Table 1. From the data in Table 1, it can be seen that human IgG The recovery rate is high, which can prove the feasibility and accuracy of the detection method in Example 1.
表1.人血清中人IgG回收率的测定(pg mL-1) Table 1. Determination of the recovery rate of human IgG in human serum (pg mL -1 )
。 .
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410192532.XA CN103969445B (en) | 2014-05-08 | 2014-05-08 | The preparation of heme-manganese dioxide composites and the method for detecting human IgG thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410192532.XA CN103969445B (en) | 2014-05-08 | 2014-05-08 | The preparation of heme-manganese dioxide composites and the method for detecting human IgG thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103969445A CN103969445A (en) | 2014-08-06 |
CN103969445B true CN103969445B (en) | 2015-09-30 |
Family
ID=51239195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410192532.XA Active CN103969445B (en) | 2014-05-08 | 2014-05-08 | The preparation of heme-manganese dioxide composites and the method for detecting human IgG thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103969445B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104964942B (en) * | 2015-07-01 | 2017-09-22 | 福州大学 | A kind of method for visualizing trace uranyl ion in quick detection water environment |
CN106526197A (en) * | 2016-10-10 | 2017-03-22 | 中南大学 | Method for detecting human IgG concentration |
CN108273554A (en) * | 2018-01-09 | 2018-07-13 | 西安交通大学 | A kind of g-C3N4The preparation and application of@Hemin compound analogue enztmes |
CN112557384B (en) * | 2020-12-10 | 2024-01-26 | 贵州大学 | Colorimetric analysis-based hydrogen sulfide detection method and application |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772012B2 (en) * | 2004-04-30 | 2010-08-10 | Quest Diagnostics Investments Incorporated | Device for detecting the presence of hemoglobin in a biological sample |
US20100239556A1 (en) * | 2006-12-13 | 2010-09-23 | TGR BioScience Pty Ltd. | Promoting ecm production by fibroblast cells and/or promoting migration of fibroblast cells in a biological system |
JP5422108B2 (en) * | 2007-10-16 | 2014-02-19 | 栄研化学株式会社 | Heme protein stabilization method and storage solution |
CN102515276B (en) * | 2011-12-30 | 2013-11-27 | 四川大学 | A method for preparing manganese dioxide nanoparticles based on bovine serum albumin as a template |
WO2013109882A1 (en) * | 2012-01-20 | 2013-07-25 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
-
2014
- 2014-05-08 CN CN201410192532.XA patent/CN103969445B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN103969445A (en) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Matveeva et al. | Myoglobin immunoassay based on metal particle-enhanced fluorescence | |
Zhu et al. | Simultaneous detection of high-sensitivity cardiac troponin I and myoglobin by modified sandwich lateral flow immunoassay: proof of principle | |
Wang et al. | Quantum dot-based lateral flow test strips for highly sensitive detection of the tetanus antibody | |
Yu et al. | Metal-linked immunosorbent assay (MeLISA): the enzyme-free alternative to ELISA for biomarker detection in serum | |
Lai et al. | A conventional chemical reaction for use in an unconventional assay: A colorimetric immunoassay for aflatoxin B 1 by using enzyme-responsive just-in-time generation of a MnO 2 based nanocatalyst | |
Orlov et al. | Highly reproducible and sensitive detection of mycotoxins by label-free biosensors | |
CN103969445B (en) | The preparation of heme-manganese dioxide composites and the method for detecting human IgG thereof | |
Yu et al. | An aggregation-induced emission-based indirect competitive immunoassay for fluorescence “turn-on” detection of drug residues in foodstuffs | |
Zuo et al. | Rapid detection of severe fever with thrombocytopenia syndrome virus via colloidal gold immunochromatography assay | |
CN104865247A (en) | Application of color development method based on nanogold aggregation to immunodetection | |
Napione | Integrated nanomaterials and nanotechnologies in lateral flow tests for personalized medicine applications | |
Rizzo | Optical immunoassays methods in protein analysis: an overview | |
Xu et al. | Chemiluminescent optical fiber immunosensor combining surface modification and signal amplification for ultrasensitive determination of hepatitis B antigen | |
CN105353116B (en) | A kind of method and its application that immunoassay is carried out based on hydrogen peroxide test strips | |
Smith et al. | Determination of ANA specificity using the UltraPlex™ platform | |
Bleher et al. | Label-free quantification of cystatin C as an improved marker for renal failure | |
Zherdev et al. | Detection limits of immunoanalytical systems: Limiting factors and methods of reduction | |
Zhao et al. | Advances in D-dimer testing: progress in harmonization of clinical assays and innovative detection methods | |
CN104677889A (en) | Method for detecting alpha fetoprotein by using magnetic immune probe based on luminol functionalization | |
CN204287199U (en) | H-FABP immunochromatographiassay assay quantitative detection test paper | |
CN104360076A (en) | Immunoassay method taking enzyme induced sulfite as activating agent | |
CN105467113A (en) | Immunoassay method based on fluorescein and luciferase bioluminescent reaction and application thereof | |
Bhardwaj et al. | Pathogenic bacteria | |
Byzova et al. | Development of rapid immunochromatographic assay for D-dimer detection | |
CA3094913A1 (en) | An improved electrode for electrochemical device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Deng Fei Inventor before: Yang Minghui Inventor before: Guo Linyan Inventor before: Zhou Miao |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160713 Address after: 610000 Sichuan city of Chengdu province Tianfu Tianfu Avenue South Huayang Street No. 846 Patentee after: Chengdu Yuanrui Biotechnology Co., Ltd. Address before: Yuelu District City, Hunan province 410083 Changsha Lushan Road No. 932 Patentee before: Central South University |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Xin Inventor before: Deng Fei |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171011 Address after: 4 Building 28, South Road, Lhasa, Tibet, 850000 Patentee after: Tibet Senwei New Energy Technology Co., Ltd. Address before: 610000 Sichuan city of Chengdu province Tianfu Tianfu Avenue South Huayang Street No. 846 Patentee before: Chengdu Yuanrui Biotechnology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180622 Address after: 610000 846, southern section of Tianfu Avenue, Huayang street, Tianfu New District, Chengdu, Sichuan Patentee after: Chengdu Yuanrui Biotechnology Co., Ltd. Address before: 850000 Sala Road, Lhasa, Tibet, 4 floor, 28. Patentee before: Tibet Senwei New Energy Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220303 Address after: 610213 Tianfu international biological city, Shuangliu District, Chengdu, Sichuan (No. 18, Section 2, biological City Middle Road) Patentee after: Changrui Biotechnology (Chengdu) Co.,Ltd. Address before: 610000 846, southern section of Tianfu Avenue, Huayang street, Tianfu New District, Chengdu, Sichuan Patentee before: CHENGDU YUANRUI BIOTECHNOLOGY Co.,Ltd. |